Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL®)

References

• United Nations Children’s Fund (UNICEF). World Health Organization, World Bank Group, United Nations. Levels & trends in child mortality, report 2019: for Child Mortality Estimation: Estimates developed by the UN Inter-agency Group for Child Mortality Estimation [Internet]. New York (NY): UNICEF; 2019 [cited 2020 Feb 20]. Available from: https://data.unicef.org/resources/levels-and-trends-in-child-mortality/
   Google Scholar
• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet [Internet]. 2019;392:1736–88. doi:10.1016/S0140-6736(18)32203-7.
   Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukṧić I, Nair H, McAllistar DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet. 2018;6:e744–e757.
   Web of Science ®Google Scholar
• Gavi the Vaccine Alliance. Pneumococcal AMC [Internet]. Geneva (Switzerland): Gavi the Vaccine Alliance; 2020 [accessed 2020 Feb 20]. https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-amc.
   Google Scholar
• Gavi the Vaccine Alliance. The 2016-2020 investment opportunity [Internet]. Geneva (Switzerland): Gavi the Vaccine Alliance; 2014 [accessed 2020 Feb 20]. https://www.gavi.org/sites/default/files/document/2019/2016-2020%20GAVI%20Alliance%20Investment%20Opportunity.pdf.
   Google Scholar
• Gavi the Vaccine Alliance. Prevent, protect, prosper: 2021-2025 investment opportunity [Internet]. Geneva (Switzerland): Gavi the Vaccine Alliance; 2020 [accessed 2020 Feb 24]. https://www.gavi.org/sites/default/files/publications/2021-2025-Gavi-Investment-Opportunity.pdf.
   Google Scholar
• International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub [Internet]. Baltimore (MD); 2019 [cited 2020 Oct 20]. Available from: www.view-hub.org.
   Google Scholar
• World Health Organization. WHO prequalified vaccines [Internet]. Geneva (Switzerland): World Health Organization; 2020 [accessed 2020 Feb 24]. https://extranet.who.int/gavi/PQ_Web/.
   Google Scholar
• Gavi the Vaccine Alliance. Gavi’s impact: the vast majority of Gavi-supported countries have introduced the pneumococcal vaccine, reaching more than 183 million children by the end of 2018 [Internet]. 2020 [accessed 2020 Mar 17]. https://www.gavi.org/types-support/vaccine-support/pneumococcal
   Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O’Brien KL. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med Internet. 2010;7(10.eng):e1000348. doi:10.1371/journal.pmed.1000348.
   PubMed Web of Science ®Google Scholar
• The Meningitis Vaccine Project. The development, licensure, introduction, and impact of a New Group A meningococcal conjugate vaccine for Africa [Issue suppl_5]. Clin Infect Dis. 2015;61:S387–S600.
   Web of Science ®Google Scholar
• Clarke E, Bashorun AO, Okoye M, Umesi A, Badjie Hydara M, Adigweme I, Dhere R, Sethna V, Kampmann B, Goldblatt D, et al. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial. Vaccine [Internet]. 2020;38(2):399–410. eng. doi:10.1016/j.vaccine.2019.08.072.
   PubMed Web of Science ®Google Scholar
• Clarke E, Bashorun AO, Adigweme I, Badjie Hydara M, Umesi A, Futa A, Ochoge M, Obayemi D, Edem B, Saidy-Jah E, et al. Immunogenicity and safety of a novel 10-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. Forthcoming.
   Web of Science ®Google Scholar
• Gavi the Vaccine Alliance. Supply agreements: 5th AMC supply agreements [Internet]. Geneva (Switzerland): Gavi the Vaccine Alliance; 2020 [cited 2020 Jun 24]. Available from: https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-amc/manufacturers/supply-agreements.
   Google Scholar
• Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial [Internet]. The Lancet. 2005;365:1139–46. doi:10.1016/S0140-6736(05)71876-6.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med [Internet]. 2014;11(6):e1001657.eng. doi:10.1371/journal.pmed.1001657.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet [Internet]. 2013;381(9862):214–22. doi:10.1016/S0140-6736(12)61854-6.
   PubMed Web of Science ®Google Scholar
• Silaba M, Ooko M, Bottomley C, Sande J, Benamore R, Park K, Ignas J, Maitland K, Mturi N, Makumi A, et al. Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis. Lancet Global Health [Internet]. 2019;7(3):e337–e34610.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet [Internet]. 2019;393(10186):2146–54. doi:10.1016/S0140-6736(18)33005-8.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper - February 2019 [Internet]. Geneva (Switzerland): World Health Organization; 2019 Feb 22. Weekly Epidemiological Report 8 (94) [cited 2020 Mar 3]. Available from: www.who.int/wer
   Google Scholar
• World Health Organization. WHO prequalified vaccines [Internet]. Geneva (Switzerland); 2020 [accessed 2020 Oct 21]. https://extranet.who.int/pqvdata/
   Google Scholar
• Gavi the Vaccine Alliance. Supply agreements [Internet]. Geneva (Switzerland); 2020 [cited 2020 Oct 21]. Available from: https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-amc/manufacturers/supply-agreements
   Google Scholar
• PATH. A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India’s 10-Valent Pneumococcal Conjugate Vaccine Administered in a 2+1 Schedule to Healthy Infants in The Gambia: NCT03896477 [Internet]; 2019 [accessed 2020 Mar 17]. https://clinicaltrials.gov/ct2/show/NCT03896477?term=Clarke&cond=Pneumococcal+Disease&cntry=GM&draw=2&rank=3
   Google Scholar
• Pan American Health Organization, World Health Organization. Expanded Program of Immunization vaccine prices for Year 2020 [Internet]. Washington (DC/United States): Pan American Health Organization; 2020 Jan 8 [accessed 2020 Feb 24]. https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=vaccines-9979&alias=51457-revolving-fund-vaccine-prices-2020&Itemid=270&lang=en.
   Google Scholar